By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 9, 2025 11:10 PM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    New Insights into Tuberculosis and Macrophage Interactions
    Health Conditions
    New Study Finds Ways to Lower Peanut Allergy Risk in Kids
    Health Conditions
    Study Links Mining Pollution to Increased ALS Risk
    Health Conditions
    Celebrities Speak Out on Ozempic and Weight Loss
    Weight Management
    Young Man’s Life Changes After Sepsis Leads to Double Amputation
    Health Conditions
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Heart Health Tips: Best Exercises for Those Over 50
    Heart Health
    The Key Habit for Longevity After 50, According to Experts
    Longevity
    Oral Health’s Crucial Role in Brain Health
    Oral Health
    Vandal with Mental Health Issues Attacks Washington State Capitol
    Mental Health
    Daily Diet Soda or Sugary Drinks Linked to Liver Disease Risk
    Healthy Living
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    Top Early Prime Day Fitness Equipment Deals Unveiled
    Fitness Trends & Tech
    U.S. Beef Demand Surges, Imports Rise to Meet Protein Craze
    Diet & Nutrition
    The Sideload 007: Exploring Technology in Running
    Fitness Trends & Tech
    Busy Philipps Inspired by Michelle Williams to Embrace Zumba
    Fitness
    Embrace Fall with These Four Seasonal Recipes
    Healthy Recipes
  • Innovation
    InnovationShow More
    Nobel Prize in Medicine Awarded for Autoimmune Research Breakthroughs
    Innovation
    Global Clean Energy Growth Surpasses Demand for Fossil Fuels
    Innovation
    Breakthrough in Mice Shows Promise for Reversing Alzheimer’s
    Innovation
    Biomea Fusion Launches Public Offering of Shares and Warrants
    Innovation
    Three Scientists Awarded Nobel Prize for Immune System Insights
    Innovation
  • News
    NewsShow More
    Connor Shaw Shares Health Update After Medical Emergency
    News
    Juan Carlos Ferrero Dismisses Cancer Rumors Amid Concern
    News
    Dengue Outbreak in Bangladesh Escalates, Urgent Action Needed
    News
    Brooks Koepka’s Wife Shares Heartbreaking Pregnancy Loss
    News
    Man with Mental Health Issues Vandalizes Washington Capitol
    News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » Innovation » Biomea Fusion Launches Public Offering of Shares and Warrants

Biomea Fusion Launches Public Offering of Shares and Warrants

By Jessica Monroe
Published: October 9, 2025
Share

Biomea Fusion, Inc., a company based in San Carlos, California, specializing in treatments for diabetes and obesity, announced on October 6, 2025, its plan to initiate an underwritten public offering of its common stock along with warrants. This offering will allow investors to purchase shares directly or through pre-funded warrants, which serve as an alternative to common stock for certain investors. Additionally, Biomea plans to allow underwriters a 30-day option to acquire an extra 15% of the offered shares and warrants.

All shares and warrants available in this proposed offering will be sold by Biomea. The company warns that the offering is subject to market conditions and other variables, so there’s no guarantee about the completion date or the specifics regarding the size and terms of the offering.

Jefferies LLC has been appointed as the sole book-running manager for this public offering. The securities being offered in this transaction are registered under an effective shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) on August 5, 2025, and received effective status on August 15, 2025.

To provide additional details about this upcoming offering, Biomea will file a preliminary prospectus supplement along with the main prospectus with the SEC. Interested parties will be able to obtain this information from Jefferies LLC through various means including mail, telephone, or email. For convenience, the SEC’s website will also have the relevant documentation available.

It’s important to note that this press release does not represent an offer to sell or solicit interest in purchasing these securities in any state or jurisdiction where such actions might be prohibited until proper registration or qualification has been achieved under the specific securities laws.

### About Biomea Fusion
Biomea Fusion focuses on developing innovative treatments for diabetes and obesity. The clinical-stage company is advancing oral small molecule therapies, icovamenib and BMF-650, which target metabolic disorders. These health issues are significant, impacting nearly half of all Americans and affecting around one-fifth of the global population. Biomea’s goal is to provide transformative therapies aimed at restoring health for individuals living with diabetes, obesity, and related conditions, ultimately striving for a cure.

### Forward-Looking Statements
This announcement includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements encompass various aspects, including Biomea’s expectations concerning the offering, market conditions that could affect the timing and size of the offering, and the company’s research and development trajectory, as well as clinical trial schedules.

Terms such as “may,” “will,” “could,” “expect,” “intend,” “believe,” and other similar phrases indicate forward-looking statements. However, not all forward-looking statements will feature these identifiers.

The forward-looking statements contained herein are based on current assumptions and beliefs of management regarding future events. These anticipations are exposed to numerous risks and uncertainties that may lead actual outcomes to diverge from what has been suggested. Factors influencing these variations include the feasibility of the proposed public offering, market conditions, and the timing of additional shares that underwriters may opt to purchase.

These risks and uncertainties are explored in detail under the “Risk Factors” section of Biomea’s latest annual report on Form 10-K, filed on March 31, 2025, along with subsequent 10-Q reports submitted to the SEC. Shareholders and stakeholders are encouraged to review these documents to better understand potential risks and uncertainties alongside other critical factors outlined in Biomea’s filings with the SEC.

As of the release date, Biomea encourages all parties to understand that these forward-looking statements reflect the company’s perspectives only at that moment and should not be considered indicative of future viewpoints. Biomea explicitly states that it has no obligation to update these statements unless legally required to do so.Drugs & Medications

TAGGED:Biomea Fusion
Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

Connor Shaw Shares Health Update After Medical Emergency

October 9, 2025

Juan Carlos Ferrero Dismisses Cancer Rumors Amid Concern

Juan Carlos Ferrero denies cancer rumors, confirming he’s healthy and ready to rejoin Carlos Alcaraz…

October 9, 2025

Heart Health Tips: Best Exercises for Those Over 50

Experts say walking, swimming, and cycling are top heart-healthy workouts for adults over 50, improving…

October 9, 2025

New Insights into Tuberculosis and Macrophage Interactions

Researchers found that lung injury and macrophage dysfunction foster TB survival, highlighting new therapeutic targets…

October 9, 2025

YOU MAY ALSO LIKE

Drones Aim to Ensure Medication Access in Maryland Communities

A new drone program in Maryland is helping isolated communities like Smith Island receive medications faster, improving access and care.

October 1, 2025

AI and Precision Mental Health: Transforming Care with Technology

AI is transforming mental health care through precision treatments, digital twins, and multi-modal diagnostics for more personalized, data-driven therapy.

October 1, 2025

Skye Bioscience’s Weight Loss Drug Underwhelms in Phase 2 Trial

Skye Bioscience shares sank 60% as its drug nimacimab missed weight-loss goals, though combo data with semaglutide hinted at potential…

October 8, 2025

Steakholder Foods to Raise $1.5 Million Through Warrant Exercise

Steakholder Foods exercises warrants to raise $1.5M, fueling its alt-protein expansion and issuing new Series A & B warrants at…

October 3, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?